This randomized clinical trial assesses whether aspirin, prophylactic-dose apixaban, or therapeutic-dose apixaban, compared with placebo, can safely reduce major adverse cardiopulmonary outcomes among symptomatic but clinically stable US outpatients with COVID-19.
Source: JAMA Online First